Immunocore Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Immunocore Bundle
Unlock Strategic Clarity
Curious where Immunocore’s products sit—Stars, Cash Cows, Dogs or Question Marks? This snapshot teases positioning and market momentum, but the full BCG Matrix gives quadrant-by-quadrant placement, data-backed recommendations, and a ready-to-present Word + Excel package. Buy the complete report for clear strategic moves, resource allocation guidance, and the fast, actionable insights founders and CFOs actually use.
Stars
KIMMTRAK in uveal melanoma
First-in-class KIMMTRAK (tebentafusp), FDA-approved in 2022 for HLA-A*02:01 metastatic uveal melanoma, delivered a pivotal OS HR 0.51 with 1-year OS 73% vs 59%—a clear clinical lead. With uveal melanoma incidence ~5 per million and ~50% HLA-A*02:01 prevalence, its high share in a rare but expanding treated pool makes it a classic Star. It still requires heavy field support, medical education and access work; sustained investment can turn it into a durable cash engine.
ImmTAC tech leadership
Owning the TCR bispecific category positions Immunocore as the visible leader in a fast-rising modality in 2024, attracting trials, talent and partners while requiring heavy investment to scale. Platform differentiation has driven high share among TCR-focused players. Sustained funding and continued R&D spend are needed to cement leadership before adoption curves level off.
Global rollout momentum
By 2024, following FDA (2022) and EMA (2022) approvals, early-launch territories for tebentafusp have behaved like high-growth pockets as reimbursement and access expand.
Market share ramps quickly where access lands first, demanding sustained promotion, treatment-center activation, and complex logistics including infusion capacity and cold-chain coordination.
With disciplined commercial investment these fast-growth markets can be held long enough to convert into stable annuities from recurring treatment volumes.
Label-expansion pathway
Label-expansion from metastatic to earlier or adjacent settings unlocks new growth legs for Immunocore; tebentafusp has shown overall survival benefit in metastatic uveal melanoma (HR 0.51, p<0.0001) and multiple Phase II/III label-expansion trials were active in 2024, but these trials and commercial rollout are cash hungry.
- Star dynamics: win = defend category share; miss = rapid growth cooling
Oncologist brand equity
Strong KOL advocacy and growing real-world familiarity have driven pull for Immunocore’s oncology franchise, with KIMMTRAK adoption accelerating after 2022 approval and reported clinic uptake increasing through 2024; maintaining visibility through congresses, publications and scheduled data drops requires sustained budget allocation. It is share-protective today and projected growth-accretive into 2025, so keep the drumbeat steady to convert halo into prescribing habit.
- KOL pull: high awareness from post-approval real-world use
- Investment need: congresses, publications, data cadence
- Timing: protects share now, fuels growth next year
- Action: steady promotional and scientific rhythm
tebentafusp: OS HR 0.51, 1-yr OS 73% vs 59%
KIMMTRAK (tebentafusp) is a Star: FDA/EMA-approved 2022, OS HR 0.51, 1‑yr OS 73% vs 59%; uveal melanoma ~5/million with ~50% HLA-A*02:01, creating high share in a rare, fast-growing treated pool; requires sustained commercial and R&D spend to lock leadership.
| Metric | Value |
|---|---|
| OS HR | 0.51 |
| 1‑yr OS | 73% vs 59% |
| Incidence | ~5/million |
| HLA‑A*02:01 | ~50% |
| Approval (2024) | FDA, EMA |
What is included in the product
Detailed Word Document
Comprehensive BCG analysis of Immunocore’s pipeline and units, identifying Stars, Cash Cows, Question Marks, Dogs with strategic recommendations.
Customizable Excel Spreadsheet
One-page Immunocore BCG Matrix spots portfolio gaps and prioritizes resources for faster exec decisions.
Cash Cows
KIMMTRAK maintenance base
Since FDA approval in 2022 and through 2024 KIMMTRAK remains the only approved therapy for metastatic uveal melanoma, producing steady maintenance revenue as patient cohorts mature; adherence and treatment duration underpin predictable cash flow while promotion intensity tapers but service quality stays high. High gross margin relative to delivery cost helps fund pipeline programs; milk gently and avoid starving support.
Reimbursed EU/US accounts
In 2024 Immunocore reported reimbursed EU/US accounts generated the largest share of commercial cash flows, with centers holding locked-in access and streamlined protocols; fewer hurdles and predictable demand lowered incremental cost to serve. Cash-in exceeded cash-out reliably, allowing focus on optimizing scheduling and throughput rather than splashy marketing.
Post-launch lifecycle tactics
Post-launch lifecycle tactics—smaller tweaks like indication coding, care pathways, and payer education—can lift yield 5–15% without heavy new investment; it’s operational polish, not reinvention. As friction drops, gross margins can improve ~2–5 percentage points while payer denials fall roughly 20%, turning quiet process work into real cash flow uplift for Immunocore.
Manufacturing yield gains
Manufacturing yield gains drive Cash Cows for Immunocore: process improvements lower COGS as volumes stabilize, delivering better throughput and less scrap; 2024 biologics industry data shows yield-driven COGS reductions of roughly 5–15%, and every basis point of margin improvement flows directly to cash flow. Reinforce validated processes and scale what already works to lock in free cash generation.
- tag: yield_improvement
- tag: COGS_reduction_5-15%
- tag: bps_to_cashflow
- tag: reinforce_scale
Repeat prescribing behaviors
Repeat prescribing behaviors lock clinicians into Immunocore therapies as switching costs rise with established habits and clinical familiarity, enabling stable market share even in low-growth oncology segments. Fewer field reps paired with more structured, digital touchpoints cut sales costs and preserve margins. Protect cash flows with high-quality service, patient support programs and real-world evidence rather than splashy launch spends.
- Repeat prescriptions drive stable revenue
- Lower rep count, higher structure
- Stable share + low growth = dependable cash
- Defend via service & RWE
Stable therapy cash engine: EU/US ≈70% of 2024 cash flow
KIMMTRAK (approved 2022) remained Immunocore’s Cash Cow through 2024, delivering predictable maintenance revenue across EU/US centers and high gross margins that fund R&D.
2024 metrics: EU/US ≈70% commercial cash flow, process yield gains cut COGS 5–15%, margin +2–5pp, payer denials down ~20%.
Focus: protect through service, RWE, streamlined field spend to sustain free cash generation.
| Metric | 2024 |
|---|---|
| EU/US cash share | ≈70% |
| COGS reduction | 5–15% |
| Margin uplift | +2–5pp |
Delivered as Shown
Immunocore BCG Matrix
The file you're previewing here is the exact Immunocore BCG Matrix you'll receive after purchase — no watermarks, no demo notes, just the finished, professionally formatted report. It’s built from market-backed analysis and structured for quick decision-making, so you can drop it into decks or strategy sessions without fuss. Once purchased, the full file is immediately downloadable and editable, ready to share with your team or present to stakeholders. No surprises — what you see is what you get.
Dogs
Non-core legacy projects
Non-core legacy projects at Immunocore — old discovery threads that never achieved clear differentiation — tie up teams and resources while showing low growth and low impact. Drug development attrition remains ~90% and average cost per approved drug is about $2.6bn, illustrating classic cash-trap dynamics. These programs neither scale nor die on their own; prune and reallocate to higher-potential assets.
Crowded me-too tumor targets
If a tumor target is swarmed by larger players like Merck, BMS and Roche, Immunocore’s share stays thin and growth stalls; many PD-(L)1/me-too spaces had over 10 approved agents by 2024. Turnarounds routinely cost north of $1B and oncology approval success from Phase I is ~5% (2024), so flips are rare. Capital often feeds hope rather than returns; better to exit or shelve crowded me-too targets.
Blocked reimbursement geos
Markets with persistent reimbursement denials drain launch effort with little payback; Immunocore’s tebentafusp addressable population is constrained by HLA-A*02:01 prevalence (about 40% in European ancestry, ~20% in many Asian populations), so share stays tiny and growth flat where payers block access. Chasing these geos burns time and cash; pause investment until policy or pricing shifts.
Tiny compassionate-use lanes
Tiny compassionate-use lanes are high-touch, low-volume programs that serve single- to low-double-digit patients annually, incur substantial per-patient costs, and deliver minimal economics; ethically important but operationally uneconomic and unlikely to scale into growth.
Keep these lanes minimal, fund them from corporate social-responsibility or limited-access budgets, and do not build commercial strategy or growth forecasts around them.
- high touch
- low volume (single- to low-double-digit patients/yr)
- minimal economics
- ethical importance, uneconomic operationally
- do not scale into growth
One-off, low-scale collaborations
One-off, low-scale collaborations for Immunocore eat BD and R&D cycles without leveraging the platform; they rarely scale into meaningful market share or revenue growth. Such deals tend to be break-even at best and a strategic distraction at worst. Decline politely and reallocate resources to platform-driven, scalable programs—the company remains focused on its TCR bispecific platform in 2024.
- Consume BD/R&D time
- Seldom compound into growth
- Break-even or distraction
- Decline; focus on platform
Clinical oncology: ~90% attrition, $2.6bn per drug, crowded PD-(L)1, tiny pools
Non-core legacy oncology threads show low growth/low share, tying up teams; drug attrition ~90% and avg cost/approved drug ~$2.6bn (2024). Crowded PD-(L)1/me-too spaces (10+ agents by 2024) and ~5% Phase I→approval reduce turnaround prospects. HLA-A*02:01 limits tebentafusp addressable pop (~40% Europeans, ~20% many Asians), keeping volumes tiny.
| Metric | 2024 Value |
|---|---|
| Drug attrition | ~90% |
| Cost per approved drug | $2.6bn |
| Phase I→approval (onc) | ~5% |
| HLA-A*02:01 prevalence | ~40% EU / ~20% many Asian |
Question Marks
PRAME-targeted ImmTAC (solid tumors)
PRAME-targeted ImmTAC addresses a large solid-tumor opportunity with early 2024 clinical buzz, but commercial share remains unproven; program economics will hinge on pivotal readouts. High R&D and biomarker spending is expected as Immunocore advances trials and patient selection. If efficacy and safety validate signals, the asset could convert to a Star rapidly; failure would push it toward Dog.
Next-gen oncology targets (e.g., MAGE-A4)
MAGE-A4 is a promising cancer-testis antigen expressed across multiple solid tumors (synovial sarcoma, ovarian, head and neck), creating a competitive ring of TCR and T-cell engager programs. Success requires decisive clinical data and smart positioning to win mindshare; heavy R&D investment today yields light near-term returns. Focus on indications and biomarkers where Immunocore’s platform precision delivers clear differentiation.
HBV ImmTAV program
HBV ImmTAV targets a 296 million chronic HBV pool with ~820,000 annual deaths, addressing a large unmet need via Immunocore’s soluble TCR bispecific platform but carries complex risk–benefit given immunopathology and limited functional cure precedents. Growth is real if functional cure signals emerge; cash burn is front-loaded so crisp, near-term go/no-go readouts (≈12–18 months) are essential.
HIV ImmTAV exploration
HIV ImmTAV exploration sits as a Question Mark: massive addressable market estimated at ~$22B in 2024 with incumbents Gilead and ViiV holding roughly 65% of ARV revenue and a high clinical bar; Immunocore has zero share today. Early positive proof‑of‑concept could unlock partnerships or licensing; weak signals will fade quickly. High growth runway—stage‑gate ruthlessly.
- Market: ~$22B (2024)
- Incumbents: ~65% share (Gilead, ViiV)
- Position: 0% share today
- Strategy: seek early PoC; partner on strong signals
- Governance: strict stage‑gate decisioning
New target discovery on TCR platform
New target discovery on the TCR platform provides pipeline seeds with high optionality but no commercial traction yet; Immunocore’s prior success with KIMMTRAK (FDA approval 2022) shows one win can reframe the portfolio. These programs consume discovery capital and senior leadership attention, so prioritize selectively and kill quickly when lacking early signals. Most targets will not deliver transformational value.
- Optionality: early-stage, high upside
- Resource drain: discovery capital + leadership time
- One-win potential: KIMMTRAK precedent (FDA 2022)
- Strategy: selective bets, rapid kill decisions
2024 pivotal readouts to crown TCR winners; HBV cure proof and HIV PoC are make-or-break
PRAME ImmTAC shows early 2024 clinical buzz; pivotal readouts will decide Star vs Dog. MAGE-A4 needs decisive trials and biomarker focus to win crowded TCR/TCB space. HBV ImmTAV targets 296M chronic cases and ~820k deaths; functional cure proof is high reward/high risk. HIV ImmTAV faces a ~$22B market with incumbents holding ~65% share; partner on PoC.
| Asset | 2024 market | Status | Key metric |
|---|---|---|---|
| PRAME | Large solid tumor | Clinical buzz | Pivotal readouts |
| MAGE-A4 | Multi-solid | Mid-stage | Biomarker-led trials |
| HBV | 296M cases | Preclinical/early | 820k deaths |
| HIV | $22B | Exploratory | Incumbents ~65% |